Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan
Background Chemotherapy-induced acute exacerbation (AEx) of idiopathic interstitial pneumonias (IIPs) seriously compromises the success of treatment of Japanese lung cancer patients. Here, we conducted a nationwide surveillance to clarify the risk of AEx and compare it with the survival benefit of c...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2020-05-01
|
Series: | ERJ Open Research |
Online Access: | http://openres.ersjournals.com/content/6/2/00184-2019.full |
id |
doaj-cb0c5fba38b64afd8768933649abc643 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yuji Minegishi Akihiko Gemma Sakae Homma Kazuma Kishi Arata Azuma Takashi Ogura Naoki Hamada Hiroyuki Taniguchi Noboru Hattori Yasuhiko Nishioka Kiminobu Tanizawa Takeshi Johkoh Takuma Yokoyama Kazutaka Mori Yoshio Taguchi Masahito Ebina Naohiko Inase Koichi Hagiwara Hiroshi Ohnishi Hiroshi Mukae Yoshikazu Inoue Kazuyoshi Kuwano Hirofumi Chiba Ken Ohta Yoshinori Tanino Fumikazu Sakai Yukihiko Sugiyama |
spellingShingle |
Yuji Minegishi Akihiko Gemma Sakae Homma Kazuma Kishi Arata Azuma Takashi Ogura Naoki Hamada Hiroyuki Taniguchi Noboru Hattori Yasuhiko Nishioka Kiminobu Tanizawa Takeshi Johkoh Takuma Yokoyama Kazutaka Mori Yoshio Taguchi Masahito Ebina Naohiko Inase Koichi Hagiwara Hiroshi Ohnishi Hiroshi Mukae Yoshikazu Inoue Kazuyoshi Kuwano Hirofumi Chiba Ken Ohta Yoshinori Tanino Fumikazu Sakai Yukihiko Sugiyama Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan ERJ Open Research |
author_facet |
Yuji Minegishi Akihiko Gemma Sakae Homma Kazuma Kishi Arata Azuma Takashi Ogura Naoki Hamada Hiroyuki Taniguchi Noboru Hattori Yasuhiko Nishioka Kiminobu Tanizawa Takeshi Johkoh Takuma Yokoyama Kazutaka Mori Yoshio Taguchi Masahito Ebina Naohiko Inase Koichi Hagiwara Hiroshi Ohnishi Hiroshi Mukae Yoshikazu Inoue Kazuyoshi Kuwano Hirofumi Chiba Ken Ohta Yoshinori Tanino Fumikazu Sakai Yukihiko Sugiyama |
author_sort |
Yuji Minegishi |
title |
Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan |
title_short |
Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan |
title_full |
Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan |
title_fullStr |
Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan |
title_full_unstemmed |
Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan |
title_sort |
acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in japan |
publisher |
European Respiratory Society |
series |
ERJ Open Research |
issn |
2312-0541 |
publishDate |
2020-05-01 |
description |
Background
Chemotherapy-induced acute exacerbation (AEx) of idiopathic interstitial pneumonias (IIPs) seriously compromises the success of treatment of Japanese lung cancer patients. Here, we conducted a nationwide surveillance to clarify the risk of AEx and compare it with the survival benefit of chemotherapy for this population.
Methods
Advanced nonsmall cell lung cancer (NSCLC) or small cell lung cancer (SCLC) patients with IIPs were retrospectively analysed. For the surveillance of first-line chemotherapy in 2009, we gathered clinical data from 396 patients who received chemotherapy at 19 institutions between January 1990 and July 2009. In a consecutive retrospective study in 2012, we analysed data from 278 patients from 17 institutions who received second-line chemotherapy between April 2002 and March 2012.
Results
Of the 396 patients analysed, 13.1% developed chemotherapy-related AEx. Combination chemotherapies of carboplatin plus paclitaxel (CP) or carboplatin plus etoposide (CE) were frequently used as first-line treatments. The lowest incidence of AEx was 3.7% in CE, followed by 8.6% in CP. In the retrospective study, 16.2% of the 278 patients developed a second-line chemotherapy-related AEx. The overall response rate by second-line chemotherapy was 7.4% in NSCLC and 25.7% in SCLC. The median overall survival from second-line and first-line chemotherapy was 8.0 and 14.3 months in NSCLC, and 8.7 and 16.0 months in SCLC, respectively.
Conclusion
Combination chemotherapies consisting of CP or CE are candidates for standard first-line treatments for patients with advanced lung cancer accompanied by IIP. Second-line chemotherapy should be considered for patients remaining fit enough to receive it. |
url |
http://openres.ersjournals.com/content/6/2/00184-2019.full |
work_keys_str_mv |
AT yujiminegishi acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT akihikogemma acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT sakaehomma acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT kazumakishi acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT arataazuma acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT takashiogura acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT naokihamada acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT hiroyukitaniguchi acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT noboruhattori acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT yasuhikonishioka acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT kiminobutanizawa acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT takeshijohkoh acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT takumayokoyama acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT kazutakamori acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT yoshiotaguchi acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT masahitoebina acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT naohikoinase acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT koichihagiwara acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT hiroshiohnishi acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT hiroshimukae acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT yoshikazuinoue acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT kazuyoshikuwano acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT hirofumichiba acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT kenohta acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT yoshinoritanino acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT fumikazusakai acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan AT yukihikosugiyama acuteexacerbationofidiopathicinterstitialpneumoniasrelatedtochemotherapyforlungcancernationwidesurveillanceinjapan |
_version_ |
1724688132823056384 |
spelling |
doaj-cb0c5fba38b64afd8768933649abc6432020-11-25T03:02:50ZengEuropean Respiratory SocietyERJ Open Research2312-05412020-05-016210.1183/23120541.00184-201900184-2019Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in JapanYuji Minegishi0Akihiko Gemma1Sakae Homma2Kazuma Kishi3Arata Azuma4Takashi Ogura5Naoki Hamada6Hiroyuki Taniguchi7Noboru Hattori8Yasuhiko Nishioka9Kiminobu Tanizawa10Takeshi Johkoh11Takuma Yokoyama12Kazutaka Mori13Yoshio Taguchi14Masahito Ebina15Naohiko Inase16Koichi Hagiwara17Hiroshi Ohnishi18Hiroshi Mukae19Yoshikazu Inoue20Kazuyoshi Kuwano21Hirofumi Chiba22Ken Ohta23Yoshinori Tanino24Fumikazu Sakai25Yukihiko Sugiyama26 Dept of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan Dept of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan Dept of Respiratory Medicine, Toho University Graduate School of Medicine, Tokyo, Japan Dept of Respiratory Medicine, Respiratory Center Toranomon Hospital, Tokyo, Japan Dept of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan Dept of Respiratory medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Dept of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Aichi, Japan Dept of Molecular and Internal Medicine Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan Dept of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan Dept of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan Dept of Radiology, Kinki Central Hospital of Mutual Aid Association of Public Teachers, Hyogo, Japan Dept of Respiratory Medicine, Kyorin University School of Medicine, Tokyo, Japan Second Dept of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan Dept of Respiratory Medicine, Tenri Hospital, Tenri, Japan Tohoku Medical and Pharmaceutical University School of Medicine, Dept of Respiratory Medicine, Sendai, Japan Tokyo Medical and Dental University, Tokyo, Japan Division of Pulmonary Medicine, Jichi Medical University, Shimono, Japan Dept of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan Dept of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan Division of Respiratory Diseases, Dept of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan Dept of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan Japan Anti-Tuberculosis Association Fukujuji Hospital, Tokyo, Japan Dept of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan Dept of Diagnostic Radiology, Saitama International Medical Center, Saitama Medical University, Saitama, Japan Nerima-Hikarigaoka Hospital, Tokyo, Japan Background Chemotherapy-induced acute exacerbation (AEx) of idiopathic interstitial pneumonias (IIPs) seriously compromises the success of treatment of Japanese lung cancer patients. Here, we conducted a nationwide surveillance to clarify the risk of AEx and compare it with the survival benefit of chemotherapy for this population. Methods Advanced nonsmall cell lung cancer (NSCLC) or small cell lung cancer (SCLC) patients with IIPs were retrospectively analysed. For the surveillance of first-line chemotherapy in 2009, we gathered clinical data from 396 patients who received chemotherapy at 19 institutions between January 1990 and July 2009. In a consecutive retrospective study in 2012, we analysed data from 278 patients from 17 institutions who received second-line chemotherapy between April 2002 and March 2012. Results Of the 396 patients analysed, 13.1% developed chemotherapy-related AEx. Combination chemotherapies of carboplatin plus paclitaxel (CP) or carboplatin plus etoposide (CE) were frequently used as first-line treatments. The lowest incidence of AEx was 3.7% in CE, followed by 8.6% in CP. In the retrospective study, 16.2% of the 278 patients developed a second-line chemotherapy-related AEx. The overall response rate by second-line chemotherapy was 7.4% in NSCLC and 25.7% in SCLC. The median overall survival from second-line and first-line chemotherapy was 8.0 and 14.3 months in NSCLC, and 8.7 and 16.0 months in SCLC, respectively. Conclusion Combination chemotherapies consisting of CP or CE are candidates for standard first-line treatments for patients with advanced lung cancer accompanied by IIP. Second-line chemotherapy should be considered for patients remaining fit enough to receive it.http://openres.ersjournals.com/content/6/2/00184-2019.full |